Effect of B-type natriuretic peptides on long-term outcomes after transcatheter aortic valve implantation.

[1]  M. Mack,et al.  Prognostic value of serial B-type natriuretic peptide measurement in transcatheter aortic valve replacement (from the PARTNER Trial). , 2015, The American journal of cardiology.

[2]  P. Wenaweser,et al.  Impact of B-type natriuretic peptide on short-term clinical outcomes following transcatheter aortic valve implantation. , 2015, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[3]  A. Mügge,et al.  B-type natriuretic peptide is a strong independent predictor of long-term outcome after transcatheter aortic valve implantation. , 2014, The Journal of heart valve disease.

[4]  A. Mügge,et al.  Three-year outcomes after transcatheter aortic valve implantation with the CoreValve prosthesis. , 2014, The American journal of cardiology.

[5]  Maurice Buchbinder,et al.  Transcatheter aortic-valve replacement with a self-expanding prosthesis. , 2014, The New England journal of medicine.

[6]  P. Pibarot,et al.  Long-term prognostic value and serial changes of plasma N-terminal prohormone B-type natriuretic peptide in patients undergoing transcatheter aortic valve implantation. , 2014, The American journal of cardiology.

[7]  M. Volpe,et al.  Natriuretic peptides in cardiovascular diseases: current use and perspectives. , 2014, European heart journal.

[8]  P. Wenaweser,et al.  Clinical outcomes of patients with low-flow, low-gradient, severe aortic stenosis and either preserved or reduced ejection fraction undergoing transcatheter aortic valve implantation. , 2013, European heart journal.

[9]  F. Gudé,et al.  Pro B-type natriuretic peptide plasma value: a new criterion for the prediction of short- and long-term outcomes after transcatheter aortic valve implantation. , 2013, International journal of cardiology.

[10]  I. Barbash,et al.  Correlation of brain natriuretic peptide levels in patients with severe aortic stenosis undergoing operative valve replacement or percutaneous transcatheter intervention with clinical, echocardiographic, and hemodynamic factors and prognosis. , 2013, American Journal of Cardiology.

[11]  Susheel Kodali,et al.  Two-Year Outcomes After Transcatheter or Surgical Aortic Valve Replacement , 2013 .

[12]  D. Leosco,et al.  Natriuretic Peptide-Guided Therapy in Chronic Heart Failure: A Meta-Analysis of 2,686 Patients in 12 Randomized Trials , 2013, PloS one.

[13]  M. Mack,et al.  Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. , 2012, Journal of the American College of Cardiology.

[14]  P. Jüni,et al.  Clinical outcomes of patients with severe aortic stenosis at increased surgical risk according to treatment modality. , 2011, Journal of the American College of Cardiology.

[15]  G. Dangas,et al.  The predictive value and evolution of N-terminal pro-B-type natriuretic peptide levels following transcutaneous aortic valve implantation. , 2011, Journal of interventional cardiology.

[16]  D. Glineur,et al.  Usefulness of B-type natriuretic peptide to predict outcome of patients treated by transcatheter aortic valve implantation. , 2010, The American journal of cardiology.

[17]  R. Tölg,et al.  Early hemodynamic and neurohormonal response after transcatheter aortic valve implantation. , 2010, American heart journal.

[18]  E. Erdmann,et al.  Utility of NT-pro-BNP in patients undergoing transapical aortic valve replacement , 2010, Clinical Research in Cardiology.

[19]  Gianni Tognoni,et al.  Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). , 2008, Journal of the American College of Cardiology.

[20]  P. Poole‐Wilson,et al.  Prognostic importance of plasma NT‐pro BNP in chronic heart failure in patients treated with a β‐blocker: Results from the Carvedilol Or Metoprolol European Trial (COMET) trial , 2007, European journal of heart failure.

[21]  J. Cohn,et al.  Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. , 2006, Clinical chemistry.

[22]  R. Califf,et al.  Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease. , 2005, JAMA.

[23]  S. Ray.  Natriuretic peptides in heart valve disease , 2005, Heart.

[24]  H. White,et al.  N-Terminal Pro–B-Type Natriuretic Peptide Levels for Dynamic Risk Stratification of Patients With Acute Coronary Syndromes , 2004, Circulation.

[25]  K. Takahashi,et al.  Natriuretic peptides in the human kidney. , 1994, Hypertension.

[26]  R. Lange,et al.  The evolution and prognostic value of N-terminal brain natriuretic peptide in predicting 1-year mortality in patients following transcatheter aortic valve implantation. , 2013, The Journal of invasive cardiology.

[27]  J. Chambers,et al.  Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. , 2009, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[28]  J. Cohn,et al.  Incremental prognostic value of changes in B-type natriuretic peptide in heart failure. , 2006, The American journal of medicine.

[29]  D. Morris.  Valve disease. , 1979, Medical times.